地尔硫卓与贝前列素对健康青年男性高原暴露后运动耐力的影响

李相俊; 王秀亮; 刘方洲; 周亮; 张伦伟; 李军; 马峰琴; 卜学惠; 常妮

doi:10.16016/j.2097-0927.202208132

您当前的位置：

首页 >

文章列表页 >

地尔硫卓与贝前列素对健康青年男性高原暴露后运动耐力的影响

军事医学 | 更新时间：2026-01-09

- 地尔硫卓与贝前列素对健康青年男性高原暴露后运动耐力的影响
- Impact of diltiazem/beprost on exercise endurance in healthy young males after high altitude exposure
- 陆军军医大学学报 2023年45卷第6期页码：480-485
- 作者机构：
  
  816099 青海格尔木，陆军第952医院心血管呼吸内科
- 作者简介：
  
  [李相俊, E-mail: lxiangjun@aliyun.com LI Xiangjun, E-mail: lxiangjun@aliyun.com
- 基金信息：
  
  全军医学科技青年培育项目(15QNP095)
- DOI：10.16016/j.2097-0927.202208132
  中图分类号： R339.4;R339.54;R969.4
- 收稿：2022-08-18，
  
  修回：2022-09-19，
  
  纸质出版：2023-03-30
- 稿件说明：
移动端阅览
李相俊, 王秀亮, 刘方洲, 等. 地尔硫卓与贝前列素对健康青年男性高原暴露后运动耐力的影响[J]. 陆军军医大学学报, 2023,45(6):480-485.

Xiangjun LI, Xiuliang WANG, Fangzhou LIU, et al. Impact of diltiazem/beprost on exercise endurance in healthy young males after high altitude exposure[J]. Journal of Army Medical University, 2023, 45(6): 480-485.
李相俊, 王秀亮, 刘方洲, 等. 地尔硫卓与贝前列素对健康青年男性高原暴露后运动耐力的影响[J]. 陆军军医大学学报, 2023,45(6):480-485. DOI： 10.16016/j.2097-0927.202208132.

Xiangjun LI, Xiuliang WANG, Fangzhou LIU, et al. Impact of diltiazem/beprost on exercise endurance in healthy young males after high altitude exposure[J]. Journal of Army Medical University, 2023, 45(6): 480-485. DOI： 10.16016/j.2097-0927.202208132.

摘要

目的

探讨单用或联合使用地尔硫卓、贝前列素对提高健康青年男性高原暴露后运动耐力的有效性及安全性。

方法

从2017年7月至2020年8月共纳入200例世居平原非藏族健康青年男性作为研究对象，从平原进驻高原(海拔2 815 m)后随机分为4组，A组: 口服地尔硫卓缓释胶囊安慰剂90 mg，1次/d；贝前列素安慰剂40 μg，3次/d。B组: 口服地尔硫卓缓释胶囊安慰剂90 mg，1次/d；贝前列素40 μg，3次/d。C组: 口服地尔硫卓缓释胶囊90 mg，1次/d；贝前列素安慰剂40 μg，3次/d。D组: 口服地尔硫卓缓释胶囊90 mg，1次/d；贝前列素40 μg，3次/d。连续干预5 d后，对比干预前后6分钟步行距离(6 minute walk distance，6MWD)及脉搏血氧饱和度(pulse oxygen saturation，SpO

)、血压(blood pressure，BP)、肺动脉收缩压(pulmonary artery systolic pressure，PASP)与不良反应等指标。

结果

13例失访，最终187例纳入数据统计。干预后B、C、D组6MWD均显著提高(

=-9.048、-9.555、-12.903，95%

: -45.582~-28.984、-46.391~-30.262、-63.205~-46.128，

＜0.05)；B、C、D组PASP均显著降低(

=10.219、9.380、11.069，95%

: 2.304~3.435、2.277~3.519、2.636~3.809，

＜0.05)；C、D组SpO

显著升高(

=-4.071、-4.655，95%

: -1.311~-0.444、-2.569~-1.031，

＜0.05)。干预后各组间比较，B、C、D组6MWD均较A组显著提高(

=7.246，

＜0.05)；PASP均较A组显著降低(

=10.421，

＜0.05)；D组SpO

较A、B、C组显著升高(

=6.896，

＜0.05)。BP、不良反应均无显著性差异。

结论

单用或联合使用地尔硫卓、贝前列素均能提升健康青年男性高原暴露后运动耐力，安全性较好。

Abstract

Objective

To investigate the efficacy and safety of single or combined use of diltiazem and beprost on exercise endurance improvement after high altitude exposure in healthy young males.

Methods

A total of 200 non-Tibet health young men who have inhabited in plain areas for generations and were transferred from plain to plateau (2 815 m) from July 2017 to August 2020 were recruited in the study. The participants were randomly assigned in group A (90 mg diltiazem sustained-release capsule placebo once a day and 40 μg beraprost placebo 3 times a day)

B (90 mg diltiazem sustained-release capsule placebo once a day and 40 μg beraprost 3 times a day). C (90 mg diltiazem sustained-release capsules once a day and 40 μg beraprost placebo 3 times a day) and D (90 mg diltiazem sustained-release capsules once a day and 40 μg beraprost 3 times a day). After 5 days' continuous administration of drug and placebo

results of 6-minute walk distance (6MWD) test

pulse oxygen saturation (SpO

)

blood pressure (BP) and pulmonary artery systolic pressure (PASP)

and incidence of adverse reactions before and after intervention were collected and compared among the groups.

Results

There were 13 cases lost during follow-up

and finally 187 participants were included. After intervention

the results of 6MWD test were obviously improved (

=-9.048

-9.555

-12.903

95%

: -45.582~-28.984

-46.391~-30.262

-63.205~-46.128

0.05)

PASP values (

=10.219

9.380

11.069

95%

: 2.304~3.435

2.277~3.519

2.636~3.809

0.05) were significantly decreased in group B

group C and group D

and the SpO

values (

=-4.071

-4.655

95%

: -1.311~-0.444

-2.569~-1.031

0.05) were greatly increased in groups C and D. In addition

the participants from the groups B

C and D obtained significantly prolonged 6MWD results (

=7.246

0.05) and lower PASP value (

=10.421

0.05) after the treatment when compared with those of group A. Moreove

SpO

in group D was significantly higher than that in groups A

B and C (

=6.896

0.05). There were no significant difference in BP value and incidence of adverse reactions.

Conclusion

Single or combined use of diltiazem and beprost can improve exercise endurance in healthy young males after high altitude exposure

with good safety.

关键词

Keywords

references

TAYLOR B J, COFFMAN K E, SUMMERFIELD D T, et al . Pulmonary capillary reserve and exercise capacity at high altitude in healthy humans[J ] . Eur J Appl Physiol, 2016, 116(2): 427-437. DOI: 10.1007/s00421-015-3299-1.

YANG T, LI X J, QIN J, et al . High altitude-induced borderline pulmonary hypertension impaired cardiorespiratory fitness in healthy young men[J ] . Int J Cardiol, 2015, 181: 382-388. DOI: 10.1016/j.ijcard.2014.12.044.

FAORO V, BOLDINGH S, MOREELS M, et al . Bosentan decreases pulmonary vascular resistance and improves exercise capacity in acute hypoxia[J ] . Chest, 2009, 135(5): 1215-1222. DOI: 10.1378/chest.08-2222.

SEHEULT R D, RUH K, FOSTER G P, et al . Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude[J ] . Respir Physiol Neurobiol, 2009, 165(2/3): 123-130. DOI: 10.1016/j.resp.2008.10.005.

王江, 黄岚. 高原性肺高血压[J]. 中国实用内科杂志, 2017, 37(5): 405-408. DOI: 10.19538/j.nk2017050103.

WANG J, HUANG L. High altitude pulmonary hypertension[J]. Chin J Pract Intern Med, 2017, 37(5): 405-408. DOI: 10.19538/j.nk2017050103.

WILLIAM M B, ALI M A S, FARGHALY H S, et al . Effectiveness and short-term survival associated with adding sildenafil to conventional therapy in the management of children with pulmonary hypertension[J ] . Prog Pediatr Cardiol, 2020, 56: 101168. DOI: 10.1016/j.ppedcard.2019.101168.

TANG P F, ZHENG X, HU X X, et al . Functional measurement of CYP2C9 and CYP3A4 allelic polymorphism on sildenafil metabolism[J ] . Drug Des Devel Ther. 2020;14: 5129-5141. DOI: 10.2147/DDDT.S268796.eCollection2020.

FUKAZAWA T, YAJIMA K, MIYAMOTO Y, et al . Evaluation of drug-drug interaction potential of beraprost sodium mediated by P450 in vitro [J ] . Yakugaku Zasshi, 2008, 128(10): 1459-1465. DOI: 10.1248/yakushi.128.1459..

VELAYATI A, VALERIO M G, SHEN M, et al . Update on pulmonary arterial hypertension pharmacotherapy[J ] . Postgrad Med, 2016, 128(5): 460-473. DOI: 10.1080/00325481.2016.1188664.

PRZYBYŁOWSKI T, TOMALAK W, SIERGIEJKO Z, et al . Polish Respiratory Society guidelines for the methodology and interpretation of the 6 minute walk test (6MWT)[J ] . Pneumonol Alergol Pol, 2015, 83(4): 283-297. DOI: 10.5603/PiAP.2015.0048.

AKSEL G, ÇORBAC 1 OǦLU Ş K, ÖZEN C. High-altitude illness: management approach[J ] . Turk J Emerg Med, 2019, 19(4): 121-126. DOI: 10.1016/j.tjem.2019.09.002.

LI Y H, ZHANG Y J, ZHANG Y. Research advances in pathogenesis and prophylactic measures of acute high altitude illness[J]. Respir Med, 2018, 145: 145-152. DOI: 10.1016/j.rmed.2018.11.004.

范玉春, 郭晓桐, 孙潇, 等. 心脏磁共振成像对慢性阻塞性肺疾病合并肺动脉高压患者肺动脉血流动力学及右心功能的临床评价[J]. 中华危重病急救医学, 2019, 31(8): 972-977. DOI: 10.3760/cma.j.issn.2095-4352.2019.08.012.

FAN Y C, GUO X T, SUN X, et al . Assessment of the hemodynamics of pulmonary artery and right ventricular function in chronic obstructive pulmonary disease with pulmonary hypertension using cardiac magnetic resonance imaging[J ] . Chin Crit Care Med, 2019, 31(8): 972-977. DOI: 10.3760/cma.j.issn.2095-4352.2019.08.012.

程晓玲. 肺动脉高压血流动力学和右心功能与预后的研究[D]. 北京: 北京协和医学院, 2017.

CHENG X L. Study on hemodynamics, right ventricular function and prognosis of pulmonary hypertension[D]. Beijing: Peking Union Medical College, 2017.

谭秀娟, 何庆. 高原肺动脉高压发病机制研究进展[J]. 心血管病学进展, 2018, 39(4): 674-677. DOI: 10.16806/j.cnki.issn.1004-3934.2018.04.043.

TAN X J, HE Q. Research progress in pathogenesis of high altitude pulmonary hypertension[J]. Adv Cardiovasc Dis, 2018, 39(4): 674-677. DOI: 10.16806/j.cnki.issn.1004-3934.2018.04.043.

DUNHAM-SNARY K J, WU D C, SYKES E A, et al . Hypoxic pulmonary vasoconstriction: from molecular mechanisms to medicine[J ] . Chest, 2017, 151(1): 181-192. DOI: 10.1016/j.chest.2016.09.001.

SITBON O, MORRELL N. Pathways in pulmonary arterial hypertension: the future is here[J]. Eur Respir Rev, 2012, 21(126): 321-327. DOI: 10.1183/09059180.00004812.

孙宁玲, 霍勇,葛均波, 等. 非二氢吡啶类钙拮抗剂在心血管疾病中应用的专家建议[J]. 中华高血压杂志, 2015, 23(3): 220-226. DOI: 10.16439/j.cnki.1673-7245.2015.03.010.

SUN N L, HUO Y, GE J B, et al . Expert advice on the application of non-dihydropyridine calcium antagonists in cardiovascular diseases[J ] . Chin J Hypertens, 2015, 23(3): 220-226. DOI: 10.16439/j.cnki.1673-7245.2015.03.010.

BARYSHNIKOVA G A, CHORBINSKAYVA S A, STEPANOVA I I, et al . Use of verapamil and dilthiasem in treating patients at high cardiovascular risk (review of literature)[J ] . Med Tr Prom Ekol, 2016(2): 15-18.

WILLIAMS B, MANCIA G, SPIERING W, et al . 2018 ESC/ESH Guidelines for the management of arterial hypertension[J ] . Eur Heart J, 2018, 39(33): 3021-3104. DOI: 10.1093/eurheartj/ehy339.

TANG Y, YAO L, LIU Z H, et al . Effect of calcium channel blockers evaluated by cardiopulmonary exercise testing in idiopathic pulmonary arterial hypertension responding to acute pulmonary vasoreactivity testing[J ] . Pulm Pharmacol Ther, 2017, 43: 26-31. DOI: 10.1016/j.pupt.2017.01.012.

王莉. 贝前列素钠在左室收缩功能不全性肺动脉高压中的应用研究[D]. 苏州: 苏州大学, 2018.

WANG L. Effect of beraprost on pulmonary hypertension due to left ventricular systolic dysfunction[D]. Suzhou: Soochow University, 2018.

程培培, 张航. 贝前列素钠治疗肺动脉高压的新进展[J]. 中国新药杂志, 2019, 28(14): 1713-1717. DOI: 10.3969/j.issn.1003-3734.2019.14.009.

CHENG P P, ZHANG H. Progress in treatment of pulmonary hypertension with beraprost[J]. Chin J New Drugs, 2019, 28(14): 1713-1717. DOI: 10.3969/j.issn.1003-3734.2019.14.009.

TIAN H, FAN F L, GENG J, et al . Beraprost upregulates KV channel expression and function via EP4 receptor in pulmonary artery smooth muscle cells obtained from rats with hypoxia-induced pulmonary hypertension[J ] . J Vasc Res, 2019, 56(4): 204-214. DOI: 10.1159/000500424.

赵宏林, 惠旭, 卢振兴, 等. 前列环素靶向药物治疗肺动脉高压的系统评价/Meta分析[J]. 中国循证医学杂志, 2018, 18(11): 1257-1266. DOI: 10.7507/1672-2531.201807086.

ZHAO H L, HUI X, LU Z X, et al . Prostacyclin drugs for pulmonary arterial hypertension: a systematic review and meta-analysis[J ] . Chin J Evid Based Med, 2018, 18(11): 1257-1266. DOI: 10.7507/1672-2531.201807086.

PICKEN C, FRAGKOS K C, EDDAMA M, et al . Adverse events of prostacyclin mimetics in pulmonary arterial hypertension: a systematic review and meta-analysis[J ] . J Clin Med, 2019, 8(4): 481. DOI: 10.3390/jcm8040481.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

线粒体分裂抑制剂Mdivi-1对高原战创伤休克大鼠的保护作用

抑郁情绪对高原新兵新训期睡眠质量的影响：负性认知加工偏向的纵向调节作用

高原军人情绪调节方式对焦虑情绪影响的交叉滞后研究

高原军人抑郁症状发展特点及与耐挫的关系研究

高原军人情绪调节方式的发展特点及其对抑郁的预测